Login to Your Account

Anatomy and avatars matter in molecularly targeted trials

By Anette Breindl
Senior Science Editor

Monday, April 3, 2017

WASHINGTON – Data from the Heracles and SUMMIT trials presented at the 2017 annual meeting of the AACR confirmed that HER2-targeting drugs can be useful both for treating various tumor types.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription